No abstract

Case Report Open AccessAmyloidosis is a rare condition that develops when an irregular protein called amyloid accumulates in the organs and interferes with their normal function. In conjunction with other disorders such as rheumatoid arthritis (RA) and psoriasis, amyloidosis may occur due to a chronic inflammatory process. With treatment of the underlying disease, amyloidosis can be addressed. Certain forms of amyloidosis can lead to life-threatening organ failure. In fact, it can involve the heart, kidneys, and nervous system. As the signs and symptoms can imitate those of more common illnesses, amyloidosis is sometimes ignored. Early diagnosis may help minimize additional injury to organs. Precise diagnosis is important, because based on the individual case, care differs greatly. Herein, we present a patient who referred to our hospital with some manifestations of RA and psoriatic arthritis (PsA) that were compatible with amyloidosis and discuss the treatment of this patient.

In December 2019, a new type of pneumonia caused by the intervention of a new member of the CORON-OVIRIDAE family, SARS-COV-2 (Acute Respiratory Syndrome Coronavirus 2), was identified in Wuhan Province, China [1]. SARS-COV-2 disease is characterized by dry cough, fever, shortness of breath, fatigue, anosmia, dysgeusia, and lymphopenia [2][3][4]. In more severe cases (15-20% of patients), onset may become more complicated with interstitial pneumonia with alveolar injury, which can clinically lead to acute respiratory distress syndrome (ARDS) and even death [5]. Coronavirus became a pandemic and forced the World Health Organization (WHO) to address the disease as a public health emergency and international concern on January 30, 2020 [6]. People with inflammatory diseases such as rheumatoid arthritis (RA) need special attention against acute coronavirus 2 (SARS-COV-2), especially against inflammatory-induced agents following coronavirus. Many of these people are at risk of severe infection, because they use immunosu-ppressive medications [7][8][9]. Patients with rheumatic disorders who are using immunosuppressive agents in the Covid-19 period may also be at risk [10]. However, some disease-modifying drugs commonly used to treat rheumatic diseases, including hydroxychloroquine, have been used as possible treatments for ; however, more research is needed on whether immune-suppressive drugs increase the risk of severe SARS-COV-2 infection in people with rheumatoid arthritis [12]. Assessing the prevalence of COVID-19 in patients with RA is important, because these patients use immunos-uppressive medications such as classic disease-